Michael Nicholas, DO
Interventional Cardiology · Dyer, INNPI 1598740748
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.4%), travel and lodging and gifts — rather than concentrated in one kind of arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.4%. Reporting peaked in 2023 at $6,430 and has fallen 97.4% since, to $168 in 2025.
Across 528 payments — averaging $42.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- W. L. Gore & Associates, Inc.$3K
- Medtronic$3K
- Penumbra, Inc.$3K
- Abbott$2K
- Novartis$1K
- plus $6K from 25 others
What the payments were for
- Travel & lodging$9,72643%
- Food & beverage$12,68056%
- Gifts$750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 65 | $3,685 |
| W. L. Gore & Associates, Inc. | 35 | $3,485 |
| Medtronic(2 entities) | 125 | $3,393 |
| Penumbra, Inc. | 9 | $2,848 |
| Abbott | 28 | $1,658 |
| Novartis | 50 | $1,031 |
| Philips North America LLC | 11 | $1,024 |
| Abiomed | 8 | $960 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $567 |
| Cardiovascular Systems Inc. | 31 | $536 |
| Johnson & Johnson | 31 | $491 |
| Biotronik Inc. | 22 | $433 |
| Inari Medical, Inc. | 16 | $407 |
| Amgen | 9 | $334 |
| Shockwave Medical, Inc | 16 | $302 |
| Boehringer Ingelheim | 3 | $245 |
| Bard Peripheral Vascular, Inc. | 8 | $222 |
| Chiesi USA, Inc. | 10 | $220 |
| Pfizer | 3 | $148 |
| E.r. Squibb & Sons, L.L.C. | 2 | $114 |
| AstraZeneca | 1 | $110 |
| Esperion Therapeutics, Inc. | 1 | $95 |
| Livanova USA, Inc. | 1 | $29 |
| Veryan Medical Incorporated | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Cook Medical LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,723
- GORE CARDIOFORM Septal Occluder$1,276
- ACCULINK$1,088
- VersaCross Access Solution$939
- GORE VIABAHN VBX Balloon Expandable Endo$925
- Impella$896
- HawkOne$894
- IGT D Peripheral$853
- Indigo$798
- GORE VIABAHN Endoprosthesis$464
- WATCHMAN Access System$300
- ENTRESTO$250
- JARDIANCE$230
- FLOWTRIEVER CATHETER, S$216
- CT THROMBECTOMY SYSTEM KIT$216
- GORE VIABAHN Endoprosthesis with Heparin$151
- IN.PACT Admiral$148
- Penumbra System$137
- CardioMEMS HF System$133
- Ranger$128
How this compares
$22,482 in reported general payments places this provider in the 85th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 174 | $162,831 |
| EliquisApixaban | 85 | $100,626 |
| EntrestoSacubitril/Valsartan | 73 | $82,581 |
| JardianceEmpagliflozin | 44 | $58,639 |
| BrilintaTicagrelor | 67 | $44,278 |
| FarxigaDapagliflozin Propanediol | 21 | $26,298 |
| Repatha SureclickEvolocumab | 20 | $24,919 |
| VascepaIcosapent Ethyl | 12 | $6,864 |
| NexletolBempedoic Acid | 11 | $4,479 |
| Ezetimibe | 170 | $4,349 |
| Icosapent Ethyl | 20 | $4,129 |
| Prasugrel Hcl | 43 | $3,618 |
| Atorvastatin Calcium | 366 | $3,598 |
| ClopidogrelClopidogrel Bisulfate | 338 | $3,508 |
| Metoprolol Succinate | 176 | $2,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $491 | $162,831174 claims |
| PfizerEliquis | $148 | $100,62685 claims |
| NovartisEntresto | $1,031 | $82,58173 claims |
| AstraZenecaBrilinta, Farxiga | $110 | $70,57588 claims |
| Boehringer IngelheimJardiance | $245 | $58,63944 claims |
| Esperion Therapeutics, Inc.Nexletol | $95 | $4,47911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Dyer
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
- Ezequiel Munoz GonzalezCarmel$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.